Zimmer Biomet (ZBH) PT Lowered to $145 at JMP Securities

JMP Securities lowered its price target on Zimmer Biomet (NYSE: ZBH) to $145.00 (from $150.00) while maintaining a Market Outperform rating.

Analyst David Turkaly cuts the PT after a downward adjustment to his modeled EPS. He remains positive on the equity noting the price is inexpensive relative to peers and believes the board will be able to locate a quality candidate for the CEO role that would alleviate the challenges the company currently faces.

You May Also Be Interested In

• Yamazaki Baking (2212:JP) PT Lowered to JPY4,100 at UBS
• Morgan Stanley Starts Carl Zeiss Meditec AG (AFX:GR) (CZMWY) at Underweight
• Jefferies Starts Nouveau Monde Graphite Inc (NOU:CN) at Buy